Does FDA’s New Potency Guidance Change Approved Cell and Gene Therapies?

Short answer: On November 2, 2026, the U.S. Food and Drug Administration issued final guidance on how manufacturers should assure the potency of cell and gene therapy products throughout development and commercial manufacturing. It did not approve a new therapy, expand an existing indication, or prove that an approved treatment now works better for every patient.

• Announcement date: November 2, 2026
• Region: United States FDA regulatory system
• Main audience: Manufacturers and applicants developing human cellular and gene therapy products
• Document change: Final guidance replacing FDA’s 2011 potency-testing guidance
• Not directly changed: Any product’s indication, prescribing criteria, insurance coverage, or approval in another country

Does “potency” mean the treatment is clinically effective?

Not by itself. In this guidance, potency means the specific ability or capacity of a product to achieve its intended therapeutic effect. Complex products made from living cells, viral vectors, or gene-editing components can be affected by differences in starting materials, manufacturing steps, storage, and delivery.

A potency assay is a quality-control tool used to measure relevant biological activity. Passing a lot-release potency standard means that a batch meets its defined quality criteria. It does not guarantee that every patient will respond, that the disease will be cured, or that benefits will outweigh risks for an individual. Clinical effectiveness and safety still require separate nonclinical evidence, clinical trials, and regulatory review.

What is new about a “potency assurance strategy”?

The FDA describes a broader lifecycle strategy rather than relying only on one final release test. The strategy connects manufacturing-process design, material controls, in-process testing, critical quality attributes, stability, and lot-release potency assays. For most products, FDA recommends at least one phase-appropriate bioassay that measures biological activity related to the intended therapeutic effect.

For licensed products, each lot generally must be tested after all manufacturing steps that could affect potency. Manufacturers must also assess whether a change in manufacturing or testing could adversely affect potency as it relates to safety or effectiveness. FDA may permit an alternative approach when it provides assurance equal to or greater than the standard method.

What does the guidance mean during clinical development?

It does not require every early-phase investigational product to begin with a fully mature commercial assay. Instead, potency assurance should become progressively stronger as product and process knowledge grows. By phase 2 or 3, the assay, controls, and acceptance criteria should be sufficiently developed for the trial’s purpose.

FDA may consider a clinical hold when potency is not adequately assured and participants could face an unreasonable and significant risk, or when an investigational new drug application lacks information needed to assess that risk. A pivotal trial can also be difficult to interpret if the potency of the clinical lots is unknown or poorly controlled and cannot be connected to the product intended for commercial use.

Which products are covered?

The scope is human cellular and gene therapy products regulated as biological products under section 351 of the U.S. Public Health Service Act. The document includes considerations for patient-specific products, products with short shelf lives, and viral-vector gene therapies, where testing time and manufacturing variability can be especially challenging.

The guidance does not apply to vaccines for infectious diseases, bacteriophage products, live biotherapeutic products, fecal microbiota for transplantation, or allergenic products. It also does not automatically change rules in South Korea, the European Union, or other jurisdictions.

What changes for patients now?

The announcement does not immediately change which treatment a hospital can offer, who qualifies, how a therapy is administered, or whether it is covered by insurance. Its practical importance is upstream: FDA has clarified how sponsors should show that batches remain biologically active and consistent from early development through delivery and post-approval manufacturing.

Someone considering a cell or gene therapy should still check the specific product’s approval status, indication, clinical evidence, authorized treatment center, known adverse effects, and long-term follow-up requirements. The existence of this manufacturing guidance is not a substitute for those product-specific facts.

Important limitations

• This is regulatory guidance for manufacturers, not a trial comparing patient outcomes.
• It does not report failure rates or lot-to-lot variability for currently marketed therapies.
• It cannot quantify how much treatment success, adverse events, availability, or development time will change.
• FDA guidance generally states the agency’s current thinking and is nonbinding unless specific statutory or regulatory requirements are cited; alternative approaches may be used if they comply with applicable law.
• The document concerns the U.S. regulatory system and does not establish approval or reimbursement elsewhere.

Primary sources

• FDA news release: FDA Provides Clarity to Support Cell and Gene Therapy Development and Quality — November 2, 2026
• FDA final-guidance landing page
• Final guidance PDF: Potency Assurance for Cellular and Gene Therapy Products — 26 pages